Health Care/Hospital

Affordable Ceretone OTC Hearing Aids Now Available at Target Stores Nationwide

LOS ANGELES, June 30, 2025 /PRNewswire/ -- Ceretone , a pioneering force in affordable hearing technology, today announces the nationwide launch of its over-the-counter (OTC) hearing aids at Target stores and Target.com. The company has established itself as a leading OTC h...

2025-06-30 22:30 1896

Noul Publishes Its Fifth Sustainability Report, Outlining a Vision for Growth and a Decade of Breakthroughs

* "The next decade will focus on securing strong growth momentum by strengthening product competitiveness and profitability" * First technology-special listed company to join the Corporate Value-Up Program… "We will grow by faithfully responding to stakeholder needs and expectations." YONGIN,...

2025-06-30 21:00 2058

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline

Interim analysis planned for January 2026 with final trial results in late 2026 Highlights: * With the 100th participant enrolled in the XanaMIA trial, the timeline for the planned interim analysis is confirmed forJanuary 2026 and the timeline for final results reconfirmed for late 2026 * An...

2025-06-30 20:30 1669

Alpha Fusion, Inc. and Curadh MTR, Inc. to Enter into Strategic Partnership to Advance Global Development of Astatine-211 Based Radiopharmaceuticals

TOKYO, June 30, 2025 /PRNewswire/ -- Alpha Fusion, Inc. ("Alpha Fusion") and Curadh MTR Inc.  ("Curadh") announced plans to enter a strategic partnership, including a Joint Venture to broadly advance the global development of Astatine-211 (At-211) based radiopharmaceuticals. The collaboration co...

2025-06-30 20:00 1743

WuXi Biologics Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL

* The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrations up to 230 mg/mL * It reduces viscosity by up to 90% while maintaining formulation stability and injectability SHANGHAI, June 30, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), ...

2025-06-30 19:00 3819

Smartee Unveils 'Live Update' to Slash Treatment Planning Time from Days to Seconds

SHANGHAI, June 30, 2025 /PRNewswire/ -- In an era where real-time treatment agility defines competitive orthodontic care, Smartee's Live Update has emerged as a game-changer for clear aligner workflows. Introduced inFebruary 2025, this new AI-powered feature on the SmarteeCheck platform is now al...

2025-06-30 15:48 1444

Enhancing Mobility and Independence: VARON Oxygen Concentrators Deliver a New Standard of Freedom and Care

NEW YORK, June 30, 2025 /PRNewswire/ -- For individuals managing respiratory conditions, every breath matters—and so does the freedom to move, explore, and live life on their own terms. At VARON , that belief is at the heart of everything we d...

2025-06-30 14:25 1366

Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms

SAN FRANCISCO and SUZHOU, China, June 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...

2025-06-30 12:04 2353

Mabwell Announces Novel Drug Technology License Agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection

SHANGHAI, June 27, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its wholly-owned subsidiary T-mab has entered into an agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection (R&D code: 8MW0511).Under the t...

2025-06-27 22:00 3555

Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management

SAN FRANCISCO and SUZHOU, China, June 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metaboli...

2025-06-27 17:49 2770

Drug-Free Nasal Spray LUCA V-Defense Creates a Protective Shield Against Viruses and Allergies

SEOUL, South Korea, June 27, 2025 /PRNewswire/ -- As respiratory illnesses like COVID-19, influenza, and Mycoplasma pneumonia continue to spread, the need for safe, non-pharmaceutical prevention options is growing. South Korea–based biotech firm LUCA AICELL has developed LUCA V-Defense Nasal Spra...

2025-06-27 16:07 1864

TransThera Publishes Translational Studies of Tinengotinib (TT-00420) against Cholangiocarcinoma on Annals of Oncology

NANJING, China and GAITHERSBURG, Md., June 27, 2025 /PRNewswire/ -- TransThera Sciences Inc. ("TransThera") announced that the translational studies of tinengotinib in CCA with acquired resistance to FGFR inhibitors were published inAnnals of Oncology (IF 56.7). Dr. Peng Peng, Vice President at T...

2025-06-27 14:26 1884

MGI ANNOUNCES PARTNERSHIP WITH NEGEDIA: ENHANCE GENOMIC SEQUENCING TECHNOLOGIES AT THE SERVICE OF SCIENTIFIC RESEARCH AND PRECISION MEDICINE IN ITALY

* In the study of rare diseases and precision medicine, understanding gene expression in the spatial context of tissues is essential. High-throughput sequencing and STOmics technology will enhance biological and molecular understanding of various pathologies. MILAN, June 26, 2025 /PRNewswire/ -...

2025-06-27 10:46 2123

WuXi AppTec Nantong Site Receives 2025 Architizer A+Award for Its Unique Blend of Technology and Humanity

SHANGHAI, June 26, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, is delighted to announce that its Nantong site (Phase I) has been recognized as the Popula...

2025-06-27 08:00 2662

NEW SINGAPORE STUDY TO ASSESS GROWING PREVALENCE AND IMPACT OF FOOD ALLERGIES

Landmark four-year joint study led by NUH and NUS Medicine, in collaboration with KKH, NUP and SSHSPH, is the first and largest to involve over 2,000 children in addressing food allergies SINGAPORE, June 26, 2025 /PRNewswire/ -- A group of clinicians and researchers from theNational University H...

2025-06-26 23:32 2365

SineuGene's SNUG01 Receives FDA Orphan Drug Designation for ALS

BEIJING, June 26, 2025 /PRNewswire/ -- SineuGene Therapeutics, a clinical-stage biotechnology company focused on gene therapies for neurological diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its gene therapy, SNUG01, for the trea...

2025-06-26 22:04 1876

Ubie Announces Cumulative Total Funding of Over $125M as US Efforts Target Expansion into Generative AI and Provider Solutions

* Ubie's growth has been accelerated by recent strategic investment and acceptance into Mayo Clinic Platform Accelerate program * Ubie's US Symptom Checker platform has seen 85% organic growth and a total user base of 4 million, helping deliver partnerships across patient advocacy and life sc...

2025-06-26 21:00 2271

Porton Advanced and EVA Pharma Sign MOU to Expand CAR T-Cell Therapy Access in The Middle East and Africa

A new era of personalized gene therapy for Leukemia patients in Egypt, Saudi Arabia, and beyond. SUZHOU, China and CAIRO, June 26, 2025 /PRNewswire/ -- Porton Advanced Solutions, a global leading cell and gene therapy CDMO service provider, andEVA Pharma, one of the leading pharmaceutical compan...

2025-06-26 21:00 1821

Angel Yeast Set to Open Baiyang Biotechnology Park in Yichang in September

YICHANG, China, June 26, 2025 /PRNewswire/ -- Angel Yeast (SH:600298) a global leader in yeast manufacturing, has announced that its Baiyang Biotechnology Park ("the Park") located in the Yichang High-Tech Zone will complete construction and commence trial production i...

2025-06-26 20:00 1927

Alebund Announces Positive Topline Results from Pivotal Phase 3 Study of AP301 for Serum Phosphorus Control in Dialysis Patients with Hyperphosphatemia

SHANGHAI, June 26, 2025 /PRNewswire/ -- Alebund Pharmaceuticals  ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for renal diseases and related chronic conditions, announced the database lock was achieved ...

2025-06-26 20:00 1830
1 ... 29303132333435 ... 308

Week's Top Stories